Cerebrolysin vs P21
A side-by-side research comparison of Cerebrolysin and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | P21 |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | <10,000 Da (peptide fraction) | ~450 Da |
| Half-life | 4-6 hours | 4-6 hours |
| Bioavailability | High (IM/IV) | Moderate (crosses BBB) |
| Typical dose | 5-30 mL | 50-100 mcg/kg |
| Frequency | Daily for 10-20 days | Daily |
| Route | Intramuscular or IV | Intranasal or Subcutaneous |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.